D. van der Heijde
- Rheumatology top 0.2%
- Immunology top 2%
- Hematology top 1%
- Molecular Biology
- Orthopedics and Sports Medicine top 5%
- Co-authors
- S van der LindenMaxime DougadosR. B. M. LandewéMartín RudwaleitJoachim SieperIgnazio OlivieriJ. BrandtFilip Van den Bosch
- Topics
- Rheumatoid Arthritis Research and Therapies (40 papers)Spondyloarthritis Studies and Treatments (27 papers)Psoriasis: Treatment and Pathogenesis (21 papers)
- Cited by
- RheumatologyHematologyImmunology
- Partner nations
- NetherlandsUnited StatesGermany
In The Last Decade
D. van der Heijde
51 papers receiving 2.4k citations
Hit Papers
Peers
Comparison fields: 5 of 78
- Rheumatology 2.3k
- Immunology 972
- Hematology 833
- Molecular Biology 197
- Orthopedics and Sports Medicine 189
Countries citing papers authored by D. van der Heijde
This map shows the geographic impact of D. van der Heijde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. van der Heijde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. van der Heijde more than expected).
Fields of papers citing papers by D. van der Heijde
This network shows the impact of papers produced by D. van der Heijde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. van der Heijde. The network helps show where D. van der Heijde may publish in the future.
Co-authorship network of co-authors of D. van der Heijde
This figure shows the co-authorship network connecting the top 25 collaborators of D. van der Heijde. A scholar is included among the top collaborators of D. van der Heijde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. van der Heijde. D. van der Heijde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 1 | |
| 3 | Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies | 0 |
| 4 | 2 | |
| 5 | Aiming for Remission in Rheumatoid Arthritis : Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen | 4 |
| 6 | Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study | 15 |
| 7 | Effect of Certolizumab Pegol Over 48 Weeks in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis | 3 |
| 8 | Effect Of Certolizumab Pegol Over 48 Weeks On Signs and Symptoms In Patients With Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Exposure | 3 |
| 9 | Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial | 1 |
| 10 | Magnetic resonance imaging assessments of patients with RA and their association with clinical and radiographic outcomes | 1 |
| 11 | Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial | 5 |
| 12 | Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial | 1 |
| 13 | 9 | |
| 14 | 19 | |
| 15 | GOLIMUMAB INHIBITS PROGRESSION OF RADIOGRAPHIC DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM THE GO-REVEAL STUDY | 9 |
| 16 | SHOULD ACPA STATUS BE REASSESSED IN PATIENTS WITH EARLY ARTHRITIS: RESULTS FROM FOLLOW-UP EXAMINATIONS IN PATIENTS WITH ARTHRITIS OF LESS THAN 16 WEEKS DURATION | 1 |
| 17 | 10 | |
| 18 | The SF-6D differentiates less in the lower ranges of the patient's utility when compared with the EQ-5D but has a better reliability and sensitivity to change | 1 |
| 19 | 112 | |
| 20 | 351 |
About D. van der Heijde
D. van der Heijde is a scholar working on Rheumatology, Immunology and Hematology, having authored 55 papers that have together received 2.5k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (40 papers), Spondyloarthritis Studies and Treatments (27 papers) and Psoriasis: Treatment and Pathogenesis (21 papers). The work is most often cited by research in Rheumatology (2.3k citations), Hematology (833 citations) and Immunology (972 citations). D. van der Heijde has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include S van der Linden, Maxime Dougados, R. B. M. Landewé, Martín Rudwaleit, Joachim Sieper, Ignazio Olivieri, J. Brandt, Filip Van den Bosch, James Cheng‐Chung Wei and Jieruo Gu. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Value in Health.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.